Vir Starts Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A

 First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu –

– Announcement follows recent U.S. government award from the Biomedical Advanced Research and Development Authority supporting development of VIR-2482 –

 Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 PENINSULA (Prevention of Illness Due to Influenza A) trial evaluating VIR-2482 for the prevention of illness due to influenza A. This trial is the first to evaluate the role of a monoclonal antibody in the prevention of influenza A illness.

VIR-2482 is an intramuscularly administered investigational monoclonal antibody that has demonstrated in vitro the ability to neutralize all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic. It is designed to be a universal prophylactic against both seasonal and pandemic influenza A, and has been engineered to have an extended half-life, providing the potential for protection throughout an entire flu season.

https://finance.yahoo.com/news/vir-biotechnology-announces-first-patient-120000431.html